Morning session of China’s 2026 on-site national reimburseme
文 / 小金
2026-09-05 08:50:03
来源:亚金网
Morning session of China’s 2026 on-site national reimbursement price negotiations and commercial-insurer innovative-drug catalogue talks opened. Company delegations queued outside and began entering; early entrants included Kangyuan Pharmaceutical, Kangpu Pharmaceutical, China Resources Sanjiu, Qidu Pharmaceutical, Zai Lab, North China Pharmaceutical, Yunding Xinyao, Qilu Pharmaceutical, Kangzhe Pharmaceutical and Joincare. Several heavyweight traditional Chinese medicine items cleared preliminary review and are now up for negotiation, notably Guangyuyuan’s Banxia Xiexin Tang granules, Tasly’s Zaoren Ningxin Diwan and Kangyuan’s Canpu granules.
